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Background: This study aimed to evaluate clinical, laboratory, ultrasound (US) and scintigraphyc parameters in
thyroid nodule and to develop an auxiliary model for clinical application in the diagnosis of malignancy.
Methods: We assessed 143 patients who were surgically treated at a single center, 65% (93) benign vs. 35% (50)
malignant lesions at final histology (1998-2008). The clinical, laboratory, scintigraphyc and US features were
compared and a prediction model was designed after the multivariate analysis.
Results: There were no differences in gender, serum TSH and FT4 levels, thyroid auto-antibodies (TAb), thyroid
dysfunction and scintigraphyc results (P = 0.33) between benign and malignant nodule groups. The sonographic
study showed differences when the presence of suspected characteristics was found in the nodules of the
malignant lesions group, such as: microcalcifications, central flow, border irregularity and hypoechogenicity. After
the multivariate analysis the model obtained showed age (>39 years), border irregularity, microcalcifications and
nodule size over 2 cm as predictive factors of malignancy, featuring 81.7% of accuracy.
Conclusions: This study confirmed a significant increase of risk for malignancy in patients of over 39 years and
with suspicious features at US.
Introduction
Thyroid nodule is a common clinical problem. Epide-
miologic studies have shown that the prevalence of palp-
able thyroid nodules are found in approximately 5% of
women and in 1% of men living in iodine-sufficient
parts of the world [1,2]. On the other hand, ultrasound
(US) studies could detect thyroid nodules in 19-67% of
selected individuals with higher frequencies mainly in
women and elderly people [3]. The majority of patients
with thyroid nodule can be managed conservatively and
it justifies the effort to select better candidates for thyr-
oidectomy [4-6].
A number of clinical, US, and cytological parameters
have been previously studied; however, none of them
have shown significant impact on clinical practice [6].
Molecular markers are promising but they have not yet
been sufficiently validated to be used in clinical practice
[7,8]. The role of clinical evaluation of patients who
have thyroid nodule is to minimize the risk of overlook-
ing thyroid cancer.
When clinical, laboratory and US parameters are
employed, there is an increase of suspicion for malig-
nancy. It includes age (< 20 or > 70 yrs.), gender (male),
large size (> 4 cm or > 2 cm in recent series), serum
t h y r o t r o p i n( T S H )l e v e l s( e v e ni nn o r m a lr a n g e s :>
1.8 mU/ml), positive thyroid auto-antibodies (TAb) and
scintigraphyc study of cold nodules [9-12]. In addition,
it has been widely perceived that malignancy rates are
higher in subjects with solitary nodules than in those
affected with multinodular goiters [5,7,9]. Although,
recent data showed that there is no correlation among
TSH levels, thyroid autoimmunity and central nodule
flow on US and color Doppler scans of thyroid cancer
[13-15]. A current study proposed a risk score analysis
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and cytopathological features (atypia) in patients who
presented indeterminate or suspicious fine-needle
aspiration (FNA) [16].
The accuracy of these clinical and laboratory aspects,
US or scintigraphic features in distinguishing benign
from malignant nodules is not well established [17,18].
This study aimed to verify predictive factors in clinical,
laboratory, US and at scintigraphyc tests, which suggest
malignancy in thyroid nodules, and to develop an auxili-
ary diagnosis model in clinical applications for manage-
ment of thyroid nodules.
Materials and methods
Population Study - Clinical Parameters
We retrospectively studied the data from 151 patients
with 194 nodules who were submitted to total or partial
thyroid surgery between 1998 and 2008 at a General
Hospital of University of Campinas, Brazil. All patients
preoperatively diagnosed with a thyroid nodule by US or
clinical examination underwent ultrasound-guided fine-
needle aspiration cytology (US-FNAC), and were
assessed retrospectively for clinical, laboratory, US and
scintigraphyc variables. From the total sample 51 thyroid
lesions and eight patients were excluded because they
lacked enough information and criteria for statistical
analysis. This study included 65% (93) benign vs. 35%
(50) malignant lesions at final histology result and a fol-
low up of patients for 33.9 ± 41.7 months. Surgery deci-
sion was made based on clinical (laboratory and US
features), cytological and image criteria (compressive
symptoms) for all cases. Indeterminate cytology was the
most common surgical indication (Table 1).
Clinical variables included age and gender, and the
demographic information took into account the patient’s
age (≥ 45 yrs.). Women were predominant in the two
groups (benign vs. malignant nodules) (Table 2).
Laboratorial variables involved TSH and free thyroxin
(FT4) levels as the baseline. TSH and FT4 were dosed
using a chemiluminescence’s analyzer, and a sandwich
technique on Roche Elecsys immunoassay analyzer,
which ranged from 0.4 to 4.5 UI/ml, and had intra-assay
variation: 13.8%; inter-assay variation: 17.5% for the
TSH and 0.9 to 1.8 ng/ml; intra-assay variation: 6.8%;
inter-assay variation: 7.8% for FT4. Thyroid autoimmunity
was defined considering elevated levels of antithyperoxi-
dase antibody (TPO-Ab), determined by immunometric
assays (reference value < 35 μUI/ml), intra-assay variation:
4.3%, inter-assay variation: 10.5% and antithyroglobulin
antibody (Tg-Ab, reference value < 49 IU/ml); intra-assay
variation: 2.3%; inter-assay variation: 8.1%.
We classified thyroid disorders in normal thyroid
function (TSH and FT4 values within the reference
ranges) as follows: autoimmu n et h y r o i dd i s e a s e( A I T D )
(euthyroid with elevated TAb); overt hypothyroidism,
elevated TSH with reduced free T4 levels); subclinical
hypothyroidism (elevated TSH and normal FT4); thyro-
toxicosis (low TSH and elevated FT4) and subclinical
hyperthyroidism (low TSH and normal free T4 and T3).
Scintigraphyc Features
The relevance of the cold nodule was evaluated using a
99 mTc-pertechnetate (Tc) scan. Twenty minutes after
intravenous injection of 10 mCi (370 MBq),
99 mTc
images were obtained on a computerized scintillation
camera equipped with a low-energy, high-resolution,
parallel hole collimator, according to validated protocol
used at our institution [19]. Nodules were reported as
cold, warm or hot.
Sonographic Parameters and US-FNAC-
Real-time US was performed by a radiology team with
experience in thyroid imaging at our institution. Internal
components of the nodule were defined as solid, mixed,
or cystic. US analyses for masses with mixed compo-
nents were evaluated on the basis of internal solid com-
ponents. The FNA was performed systematically in
nodules ≥ 1 cm in diameter. US features defined size
and suspicious parameters of malignancy [6,17] as fol-
lowing: hypoechogenicity, microcalcifications, border
irregularity and central flow by Doppler study. The con-
firmed presence of one of these characteristics defined
the nodule as positive at US findings (suspicious malig-
nant nodule) being the FNA study indicated in nodule <
1 cm [6] diameter. If a nodule did not show suspicious
features it was classified as probably benign (negative
US findings). The nodule size and presence of other
nodules within thyroid were also noted and classified as
single/solitary vs. multinodular goiter. In multinodular
goiter group the most suspicious nodule was included in
the study. Longitudinal and transverse views of thyroid
were obtained. The US-FNAC was performed in the
nodules using a 22-gauge needle without local anesthe-
sia. If the aspirate was hemorrhagic a 25-gauge needle
was used. Aspiration was expressed on frosted-end glass
Table 1 Criteria for Surgical Treatment of Thyroid Nodule
in a Single Center
Surgical Criteria N %
Clinical/Compressive symptoms 26 18.7%
Inconclusive FNAC 14 10.2%
Scintigraphy - Cold Nodule 06 4.3%
FNAC diagnosis 13 9.35%
FNAC suspect (indeterminate) 50 35.9%
FNAC suspect + US features 27 19.4%
US suspect features 03 2.15%
FNAC: fine-needle aspiration cytology; US: ultrasound.
Maia et al. Head & Neck Oncology 2011, 3:17
http://www.headandneckoncology.org/content/3/1/17
Page 2 of 7slides, air-dried, and stained using Papanicolaou’s
method [20]. For each sample, at least three slides were
obtained for cytological analysis.
Cytological Features
Cytological analysis was based on the Bethesda classifi-
cation system [21]. All slides from FNAC findings were
re-analyzed by an expert cytopathologist of our Pathol-
ogy Department (P.S.M) in order to confirm the results.
After obtaining the previous pathology reports the cytol-
ogist reviewed them and reclassified the cases using the
Bethesda system according to the microscopic features
which were described on the existing pathology reports.
This review of slides was blind to outcomes. The FNAC
result was reclassified into six categories: unsatisfactory
(I), benign (II), follicular lesion of undetermined signifi-
cance (III), follicular neoplasm (IV), suspicious of malig-
nancy (V) and malignancy (VI) (Table 3). Benign
cytologic findings included colloid nodules, adenoma-
tous hyperplasia, lymphocytic thyroiditis and toxic dif-
fuse goiter. The indeterminate category (III and IV)
included: follicular lesion, Hurtle Cell tumor, and an
atypical presentation so that malignancy could not be
excluded (Figure 1). Follicular neoplasm showed follicle
formation, high cellularity, microfollicles, scant colloid,
and no nuclear features of papillary thyroid cancer
(PTC). The FNAC findings were considered suspicious
for PTC when papillary structures were found, and also
had nuclear enlargement, intranuclear inclusions or
nuclear grooves. The unsatisfactory sample was define
as the absence of at least six follicular cell groups, each
one containing 10-15 cells derived from at least two
aspirates of a nodule according to the American Thyroid
Association (ATA) guidelines. We did not include the
unsatisfactory samples in calculations. The findings of
malignancy were confirmed by means of surgery.
Statistical Analysis
This study was approved by our institutional review
board. For the univariate analysis, data was analyzed
using chi-square test, or Fisher’s exact test to categorical
variables, and the non-parametric test (Mann-Whitney)
to quantitative variables of the two groups (P < 0.05).
For the multivariate analysis, a logistic regression model
was applied to data, using the predictors of malignancy
that was statistically significant in the univariate analysis.
To analyze the relationship between age and thyroid
nodule malignancy, we created a receiver operating
characteristic (ROC) loop to identify cutoff points to
enable identification of specificity and sensitivity of age
related to thyroid cancer (Figure 2). Finally, we created
a diagnostic predictor model based on data from the
multivariate analysis and tested it for accuracy in predic-
tion of thyroid malignancy. Statistical analyses were per-
formed using the SPSS version 13.0.
Results
Malignancy in thyroid nodules was associated to age and
suspicious sonographic features. There were no differ-
ences in gender (AOR 1.35, 95% CI 0.53-3.42, P = 0.52),
serum TSH levels (P = 0.11), FT4 levels, thyroid auto-
antibodies (TAb), thyroid auto-immune disease and thyr-
oid dysfunction (hypo and hyperthyroidism) between the
Table 3 FNAC Result and Histology Correlation of
Thyroid Nodules - Accuracy of FNAC in the Preoperative
FNAC Final Histology Total
Bethesda Category* Benign Malign
II 24 (80%) 6 (20%) 30 (21.7%)
III 45 (93.8%) 3 (6.2%) 48 (34.8%)
IV 16 (47.1%) 18 (52.9%) 34 (24.6%)
V 05 (31.2%) 11 (68.8%) 16 (11.6%)
VI - 10 (100%) 10 (7.3%)
Total 90 48 138 (100%)
The sensitivity, specificity, positive predictive value and negative predictive
value of FNAC were 82.8%, 97.7%, 80%, 80.7%, respectively.
*FNAC: fine-needle aspiration cytology; II: benign; III: follicular lesion of
undeterminate significance; IV: follicular neoplasm; V: suspicious of
malignance; VI: malignant.
Table 2 Clinical and Laboratory Variables of Patients under Thyroid Nodule Evaluation in a Single Center
Variables Benign Malignant Total P-value
Patients (n) 93 50 143 -
Age (months) 48.6 ± 11.9 44.6 ± 16.5 47.2 ± 13.7 0.23
Age ≥ 45 yrs. (%) 68.5% 31.5% 65% 0.24
Gender (Female) (%) 86% 51.3% 84.6% 0.52
TSH (mU/ml) [median] 1.37 1.82 1.47 0.11
FT4 (mU/ml) [median] 1.23 1.28 1.24 0.51
TAb positively (%) 23.6% 15.6% 21.2% 0.36
Auto-Immune Disease (%) 24.7% 14.7% 21.5% 0.24
Normal Thyroid function (n) 68 42 110 0.30
Hyperthyroidism (Graves) (n) 15 04 19 0.61
Hypothyroidism(n) 10 04 14 0.15
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clinical significant predictor of malignancy (AOR 2.95,
95% CI 1.34-6.46, P = 0.007) and an age cutoff of 38.5
years was applied to the ROC curve analysis (Figure 2).
The multiple logistic regression to analyze gender, age,
solitary nodularity, and TSH concentration confirmed a
significant increased adjusted odds ratios (AOR) for
malignancy in patients of > 39 years. The solitary nodules
were not at increased risk (AOR 1.10, 95% CI 0.83-1.46,
P = 0.48) in our study. Results of scintigraphyc showed
the presence of cold nodules in 62.5% of malignant
nodules (Figure 3) vs. cold nodules in 76.9% of benign (P
= 0.33). The warm or hot nodules were not considered a
predictive for malignancy on thyroid nodule investigation
(P = 0.25).
The sonographic assessment showed a larger mean
size in benign nodules (2.23 ± 1.82 vs. 2.87 ± 1.65 cm;
P = 0.003) and a positive US in the malignant group,
including: microcalcifications, central vascularity, border
irregularity, and hypoechogenicity (Table 4). The nodule
≥ 2 cm in diameter was also a significant predictor of
malignancy. After multivariate analysis, detection of
simultaneously presence of age > 39 yrs., border irregu-
larity, microcalcifications and nodule ≥ 2 cm in diameter
by US study, a high accuracy to identify malignant thyr-
oid nodules was shown (Table 5). The border irregular-
ity and microcalcifications constituted the strongest
predictors of malignancy after multivariate analysis. The
hypoechogenicity and central flow were significant in
the univariate analysis only.
Discussion
The predictor model shows a high accuracy (> 80%)
for malignant thyroid nodule when it includes age
(≥ 38.5 years.), border irregularity, microcalcifications,
and nodule size (≥ 2 cm) using high-resolution ultra-
sound. In our study, scintigraphyc study was not useful
to differentiate the two groups. The number of nodules
(solitary vs. multiple) did not predict malignancy. No
other clinical or laboratory parameters were significant
in this study, including auto-immune disease and TSH
Figure 1 a) A Category IV of Bethesda System (follicle formation, high cellularity, microfollicles, scant colloid, and no nuclear features
of papillary thyroid cancer - Papanicolaou’s stain); b) Histology result confirmed minimal invasive follicular carcinoma.
Figure 2 Age cutoff of 38.5 years by ROC-curve analysis as an
independent risk predictor factor of thyroid malignancy:
sensitivity of 82.9% and specificity of 38%, with 56.1% of
accuracy for malignancy in 143 patients at a single center.
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retically help both the patient and the surgeon to make
a better decision upon the extent of recommended
surgery.
Age in thyroid nodule patients was identified as an
independent predictor for malignancy with an age cut
off of ≥ 38.5. Baier et al (2009) reviewed reports of 944
thyroid nodules of four sonographic features and found
statistical significance in malignant nodules in young
patients (≤ 45 years) and solid nodule morphology [22].
Several studies have tried to predict malignancy in thyr-
oid nodules with indeterminate or suspicious FNA find-
ings according to the M.D. Anderson Cancer Center
series [23]. The ROC-curve of our data shows a different
age cutoff to predict malignancy during thyroid nodule
evaluation, providing good accuracy and high sensitivity
rate. In fact, the application of the International Union
against Cancer (AJCC/UICC) classification system based
on pTNM parameters and in age is recommended for
tumors of all types, including thyroid cancer [6], because
it provides a useful shorthand method to describe the
extent of the tumor. Age is one of the criteria, with cut-
off of over 45 years that is in disagreement with the
findings showed in our data, which agree with the
Banks and Baier et al study [16,20].
The importance of TSH levels as a predictor of malig-
nancy in thyroid nodule evaluation, have been discussed
in recent studies showing that an elevated serum TSH
concentration might be associated to increased risk of
different thyroid cancers in patients with nodular goiter
[11,12,15]. Higher TSH values, even within normal
ranges, have been associated with a greater risk of thyr-
oid malignancy in some studies [11-15]. Boelaert et al
(2006) studied 1.500 consecutive patients without overt
thyroid dysfunction and found a significant increase in
adjusted odds ratios (AORs) for the diagnosis of malig-
nancy in subjects with serum TSH 1.0-1.7 mU/liter
compared to TSH less than 0.4 mU/liter (AOR 2.72),
with further increases being evident in those with TSH
1.8-5.5 mU/liter (AOR 3.88). Males, younger patients,
and those with clinically solitary nodules were also at
increased risk [12]. We did not observed correlation of
gender or solitary nodule in our data. The TSH concen-
tration was not significant after multivariate analysis in
our study in accordance with some authors [15] and in
Figure 3 a) Scintigraphyc scan showing cold nodule in euthyroid female patient of 34 years old; b) Histology result confirmed benign
follicular nodule (an adequately cellular specimen comprised of varying proportions of colloid and benign follicular cells arranged as
macrofollicles and macrofollicle fragments).
Table 4 Ultrasound Parameters of Malignancy of the 143
Patients that underwent Thyroid Nodule Evaluation in a
Single Center
Variables Benign Malign P-value
N% N%
Nodules (n) 93 50
Nodule (number)/patient 1.58 ± 1.15 1.73 ± 1.31 0.51
Nodule size (cm) 2.87 ± 1.65 2.23 ± 1.82 0.003
Nodule size (range) [cm] 0.3 - 9.3 0.3 - 9.0
Microcalcifications 12 14.1% 20 45.5% < 0.001
Macrocalcifications 15 17.6% 04 9.09% 0.06
Border Irregularity 15 17.8% 34 75.5% < 0.001
Hypoechogenicity 36 42.3% 32 71.1% 0.003
Hyperechogenicity 31 36.4% 06 13.3% 0.001
Size ≥ 2 cm 64 73.5% 23 46.0% 0.001
Internal Flow 13 21.6% 17 56.6% < 0.001
Absent Flow 27 45.0% 06 20.0% < 0.001
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way unclear to date and needing further investigation.
In our data correlation with thyroid auto-immunity
and malignancy was not found. In the majority of the
previous retrospective studies, there is a support for the
correlation between thyroid malignancy and Hashimo-
to’s thyroiditis (HT) [24-30]. A current review of the
American Thyroid Associationg u i d e l i n e sf o rt h y r o i d
nodules and thyroid cancer stated that rate of malig-
nancy in nodules in thyroid glands involved with HT
could be possibly higher [6,31]. In a recent study by
Anil et al (2010), a malignancy rate of 1.0% in HT
group (2 out of 191 nodules) vs. 2.7% in the control
group (19/713) was demonstrated, although no statisti-
cal significance was found even at higher TSH levels
[31] that is similar to our results.
Thyroid ultrasound is used to evaluate index of nodule
size, location, characteristics, number and presence of
additional thyroid nodules and to detect suspicious
appearance of lymph nodes [17]. Nodule size has been
pointed out not to be a predictive of malignancy
[6,11,12,18]. Patients with multiple thyroid nodules have
the same risk for malignancy as those with solitary
nodules. Is recommended that all patients with nodular
thyroid glands should be submitted to US evaluation
[6,18]. Our data showed correlations of thyroid malig-
nancy with nodules which presented microcalcifications,
border irregularity, size ≥ 2 cm, central flow by Doppler
and hypoechogenicity after US study. After a multiple
logistic regression border irregularity and microcalcifica-
tions were the strongest predictors of malignancy in
thyroid nodule, followed by the nodule over 2 cm in
diameter.
Gonzalez-Gonzales (2010) evaluated the efficiency of
diagnostic of sonographic findings and compared to
those of FNA biopsy of thyroid nodules to study US
characteristics of 341 thyroid nodules. The multivariate
logistic regression revealed that the only variable, which
kept a significant association with malignancy, was the
presence of microcalcifications [18]. These data confirm
the study by Li QS (2010) who retrospectively reviewed
115 nodules (104 patients) with PTC. They also ana-
lyzed thyroid nodules and cervical lymph nodes size,
border, calcification, echotexture, hemodynamic on US.
The microcalcifications showed an increased in suspi-
cion for malignancy of thyroid nodule [32]. A hypoe-
choic thyroid nodule with increased internal vascularity,
ill-defined border and microcalcifications, PTC was
strongly suggested, which is similar to our data.
The color Doppler analysis was not correlated to thyr-
oid malignancy in our study, which agrees with cur-
rently data in the literature. Moon et al (2010) evaluated
1083 thyroid nodules, 814 benign and 269 malignant.
The central flow was frequently seen in benign nodules
and the absence of vascularity was more frequent in
malignant nodules. Vascularity itself or a combination of
vascularity and gray-scale US features was not as useful
as the use of suspicious gray-scale US features alone for
predicting thyroid malignancy [13], similar to the data
of Cantisani et al (2010) of 1.090 assessed patients [14].
In their study, they concluded that pattern III cannot be
used to predict malignancy with confidence, and FNA
still is mandatory to remove the nature of the nodule.
Choi et al (2009) followed up 165 patients with indeter-
minate cytology diagnosed as follicular neoplasm and
no difference in malignancy incidence on gender; age
(≥ 45 years), nodule size and US features were found.
Only central color Doppler flow was predictive for
malignancy in follicular neoplasm [33]. However, Anil et
al (2010) showed that US features of nodule echogeni-
city, structure, margin, and Doppler flow were similar in
patients with Hashimoto’s thyroiditis and in control
group [31].
Banks et al (2008) proposed a risk score analysis based
on patient age (50 yrs), nodule size (2.5 cm) and cyto-
pathological features (atypia) for patients with indeter-
minate or suspicious FNAC [16]. They observed a
nonlinear relationship between age and risk of malig-
nancy, and patients at both age extremes were more
likely to have malignant thyroid nodules.
A predictor model was created using variable of age
(> 39 years), border irregularity, microcalcifications and
nodule diameter (>2 cm) to identify thyroid malignancy
with good accuracy (>80%). Is important to highlight that
to understand the combination of age and US parameters
in malignancy prediction is essential for clinicians to
make decisions, and to guide surgical definition in many
cases. The TSH level, the presence of auto-immune
Table 5 Independent risk factors of thyroid malignancy from a single center: Predictor Model Accuracy of 81.7%**
Variables Adjust Odds Ratio 95% Confidence Interval P-value
Age at Diagnosis (≥ 39 years) 7.26 1.79 - 29.3 0.005
Microcalcifications* 10.28 1.62 - 64.8 0.013
Border Irregularity* 18.82 5.18 - 68.3 < 0.001
Size ≥ 2 cm* 6.20 1.74 - 22.1 0.005
*Ultrasound parameters.
**Multiple logistic regression analysis considering age, nodule size and ultrasound features at presentation.
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ferentiation in the two groups. Male gender, solitary
nodule or Hashimoto’s thyroiditis were also not consid-
ered predictors of malignancy in our study.
Risk prediction, based on clinical and US parameters,
should be used as an adjunct the findings of FNA aiming
to identify patients who require further investigation and/
or surgical intervention. Prospective studies are required
to define the role of this risk prediction to improve clini-
cal management in a larger patient population.
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